• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparative study of on-label versus off-label treatment of intracranial aneurysms with the Pipeline embolization device
CONCLUSIONS: In real-world practice, off-label use of PED is common and can achieve similar efficacy as on-label use. However, in aggregate, off-label use was found to carry an increased rate of ischemic complications. With judicious attention to safety and individual patient characteristics, these results highlight the scale and general feasibility of off-label PED use by experts.PMID:35090133 | DOI:10.3171/2021.11.JNS212481
Source: Journal of Neurosurgery - January 28, 2022 Category: Neurosurgery Authors: Samuel J Cler David C Lauzier Arindam R Chatterjee Joshua W Osbun Christopher J Moran Akash P Kansagra Source Type: research

An observational epidemiological study to analyze intracerebral hemorrhage across the United States: Incidence and mortality trends from 1990 to 2017
Intracerebral Hemorrhage (ICH) accounts for 10% of strokes annually in the United States (US). Up-to-date trends in disease burden and regional variations remain unknown. Our study reports updated trends of ICH incidence, mortality, and mortality to incidence ratio (MIR) across the US.
Source: Journal of Stroke and Cerebrovascular Diseases - January 25, 2022 Category: Neurology Authors: Augustin J. DeLago, Harpreet Singh, Chinmay Jani, Arashdeep Rupal, Joseph Shalhoub, Richard Goodall, Darshil Shah, Adam Hartley, Matthew Hammond-Haley, Dominic C. Marshall, Martin Gizzi, Mahmood AbdelRazek, Justin D. Salciccioli Source Type: research

Periprocedural safety of saccular aneurysm embolization with the Penumbra SMART Coil System: a SMART registry subset analysis
Conclusion The low rates of thromboembolic complications and RRP events demonstrate the adequate safety profile of the SMART Coil System to treat cerebral aneurysms in routine clinical practice. Trial registration number NCT02729740.
Source: Journal of NeuroInterventional Surgery - January 18, 2022 Category: Neurosurgery Authors: Starke, R. M., Park, M. S., Bellon, R., Bohnstedt, B., Schirmer, C. M., De Leacy, R., Fiorella, D., Yoo, A. J., Spiotta, A. M., On behalf of the SMART Registry Investigators Tags: Open access, Hemorrhagic stroke Source Type: research

Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study
AbstractStroke is the third leading cause of death in the United States and the leading cause of adult disability. Despite enormous research efforts including many clinical trials, tissue plasminogen activator (tPA) remains the only FDA-approved treatment for acute ischemic stroke. Unfortunately, only 1 –3% of stroke patients in the US receive this therapy because of the narrow time window and severe side effects for using tPA. The most deadly and damaging side effect is the risk of intracranial bleeding or hemorrhage. For that reason, the dose of tPA and its overall administration are under tigh t control, which may com...
Source: Journal of Thrombosis and Thrombolysis - November 10, 2021 Category: Hematology Source Type: research

Epidemiology of stroke in the last decade: a systematic review
CONCLUSION: There are few studies that analyse the incidence of CVD and even fewer that analyse its evolution. The overall median remains high, although the figures are heterogeneous across studies. Worldwide the trend is towards its decrease, and there are geographical areas, especially in Asia, with an alarming upward trend.PMID:34676530 | DOI:10.33588/rn.7309.2021138
Source: Revista de Neurologia - October 22, 2021 Category: Neurology Authors: F Purroy N Montal à Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13